CH653346A5 - Analoga der neurohypophysaeren hormone oxytocin und vasopressin mit inhibierungseigenschaften gegenueber der aktivitaet dieser natuerlichen hormone. - Google Patents

Analoga der neurohypophysaeren hormone oxytocin und vasopressin mit inhibierungseigenschaften gegenueber der aktivitaet dieser natuerlichen hormone. Download PDF

Info

Publication number: CH653346A5
Authority: CH; Switzerland
Prior art keywords: hormones; oxytocin; mixture; analogs; inhibitory
Prior art date: 1982-05-10

Application number

CH2530/83A

Other languages

German (de)

English (en)

Inventor

Tomislav Dr Barth

Karel Dr Dr Sc Jost

Michal Lebl

Alena Dr Machova

Linda Dr Servitova

Jirina Dr Slaninova

Original Assignee

Ceskoslovenska Akademie Ved

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-05-10

Filing date

1983-05-09

Publication date

1985-12-31

1982-05-10 Priority claimed from CS823340A external-priority patent/CS226923B1/cs

1982-08-26 Priority claimed from CS620582A external-priority patent/CS229895B1/cs

1982-08-26 Priority claimed from CS620482A external-priority patent/CS229894B1/cs

1982-08-27 Priority claimed from CS627182A external-priority patent/CS230327B1/cs

1983-05-09 Application filed by Ceskoslovenska Akademie Ved filed Critical Ceskoslovenska Akademie Ved

1985-12-31 Publication of CH653346A5 publication Critical patent/CH653346A5/de

Links

101800000989 Oxytocin Proteins 0.000 title description 11
229960001723 oxytocin Drugs 0.000 title description 10
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title description 9
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title description 9
230000000694 effects Effects 0.000 title description 8
230000002401 inhibitory effect Effects 0.000 title description 8
229940088597 hormone Drugs 0.000 title description 7
239000005556 hormone Substances 0.000 title description 7
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title description 6
108010004977 Vasopressins Proteins 0.000 title description 6
102000002852 Vasopressins Human genes 0.000 title description 6
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title description 6
229960003726 vasopressin Drugs 0.000 title description 6
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
229910052739 hydrogen Inorganic materials 0.000 description 20
239000000203 mixture Substances 0.000 description 20
229910052799 carbon Inorganic materials 0.000 description 15
239000000243 solution Substances 0.000 description 15
229940024606 amino acid Drugs 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
235000011054 acetic acid Nutrition 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
238000004809 thin layer chromatography Methods 0.000 description 10
239000000126 substance Substances 0.000 description 9
102400000050 Oxytocin Human genes 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
-1 aromatic amino acid Chemical class 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
239000001257 hydrogen Substances 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
238000010828 elution Methods 0.000 description 6
MRNKEVGKBFIFET-AHCPCVRLSA-N (2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(4s,7s,10s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carb Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 MRNKEVGKBFIFET-AHCPCVRLSA-N 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
108700042417 deamino-6-carba- oxytocin Proteins 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
150000002431 hydrogen Chemical group 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
JGLCYGDOFQBJND-AVGNSLFASA-N (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(2S)-2-amino-4-sulfanylbutanoyl]pyrrolidine-2-carboxamide Chemical compound N[C@@H](CCS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N JGLCYGDOFQBJND-AVGNSLFASA-N 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000003191 uterotonic effect Effects 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
108010070873 Posterior Pituitary Hormones Proteins 0.000 description 3
102000005320 Posterior Pituitary Hormones Human genes 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000004811 liquid chromatography Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
150000008574 D-amino acids Chemical group 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
VVNCNSJFMMFHPL-GSVOUGTGSA-N L-penicillamine Chemical compound CC(C)(S)[C@H](N)C(O)=O VVNCNSJFMMFHPL-GSVOUGTGSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000008859 change Effects 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
108700027018 deaminooxytocin Proteins 0.000 description 1
GTYWGUNQAMYZPF-QPLNMOKZSA-N demoxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 GTYWGUNQAMYZPF-QPLNMOKZSA-N 0.000 description 1
229960000477 demoxytocin Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
238000000034 method Methods 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CH2530/83A 1982-05-10 1983-05-09 Analoga der neurohypophysaeren hormone oxytocin und vasopressin mit inhibierungseigenschaften gegenueber der aktivitaet dieser natuerlichen hormone. CH653346A5 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
CS823340A CS226923B1 (cs)	1982-05-10	1982-05-10	Analogy oxytocínu s inhibičnlm účinkem a způsob jejicb výroby
CS620582A CS229895B1 (cs)	1982-08-26	1982-08-26	Analog oxytocinu a způsob jeho výroby
CS620482A CS229894B1 (cs)	1982-08-26	1982-08-26	Analog vasopresinu a způsob jeho výroby
CS627182A CS230327B1 (en)	1982-08-27	1982-08-27	Oxytocine analogue and method of preparing same

Publications (1)

Publication Number	Publication Date
CH653346A5 true CH653346A5 (de)	1985-12-31

Family

ID=27430101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH2530/83A CH653346A5 (de)	1982-05-10	1983-05-09	Analoga der neurohypophysaeren hormone oxytocin und vasopressin mit inhibierungseigenschaften gegenueber der aktivitaet dieser natuerlichen hormone.

Country Status (9)

Country	Link
BE (1)	BE896685A (da)
CH (1)	CH653346A5 (da)
DE (1)	DE3317092A1 (da)
DK (1)	DK199983A (da)
FR (1)	FR2526318B1 (da)
GB (1)	GB2121052B (da)
IT (1)	IT1164212B (da)
NL (1)	NL8301663A (da)
SE (1)	SE460051B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT398767B (de) *	1988-05-26	1995-01-25	Gebro Broschek Gmbh	Verfahren zur reinigung eines rohpeptids mittels präparativer mitteldruckflüssigkeitschromatographie
JP2003335797A (ja) *	2000-06-28	2003-11-28	Daicel Chem Ind Ltd	ペプチド化合物及びそれを有効成分とする医薬組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CS216722B1 (en) *	1980-06-24	1982-11-26	Michal Lebl	Oxytocine analogues and method of making the same

1983
- 1983-05-05 GB GB08312320A patent/GB2121052B/en not_active Expired
- 1983-05-05 DK DK199983A patent/DK199983A/da not_active Application Discontinuation
- 1983-05-06 BE BE0/210719A patent/BE896685A/fr not_active IP Right Cessation
- 1983-05-09 FR FR8307696A patent/FR2526318B1/fr not_active Expired
- 1983-05-09 SE SE8302643A patent/SE460051B/sv not_active IP Right Cessation
- 1983-05-09 IT IT21002/83A patent/IT1164212B/it active
- 1983-05-09 CH CH2530/83A patent/CH653346A5/de not_active IP Right Cessation
- 1983-05-10 NL NL8301663A patent/NL8301663A/nl not_active Application Discontinuation
- 1983-05-10 DE DE19833317092 patent/DE3317092A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
GB2121052B (en)	1985-08-14
GB8312320D0 (en)	1983-06-08
NL8301663A (nl)	1983-12-01
FR2526318A1 (fr)	1983-11-10
FR2526318B1 (fr)	1986-11-14
SE8302643D0 (sv)	1983-05-09
DK199983D0 (da)	1983-05-05
IT1164212B (it)	1987-04-08
SE8302643L (sv)	1983-11-11
DK199983A (da)	1983-11-11
DE3317092A1 (de)	1983-11-10
GB2121052A (en)	1983-12-14
SE460051B (sv)	1989-09-04
IT8321002A1 (it)	1984-11-09
IT8321002A0 (it)	1983-05-09
BE896685A (fr)	1983-09-01

Legal Events

Date	Code	Title	Description
1992-01-31	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
CA1185235A (en)	1985-04-09	Antagonists of the antidiuretic and/or vasopressor action of arginine vasopressin
EP0001295B1 (de)	1982-03-17	Somatostatin-analoge Cyclopeptide, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Anwendung
CH632738A5 (de)	1982-10-29	Peptide mit gonadoliberin-wirkung und verfahren zu ihrer herstellung.
DE2256445C3 (de)	1981-11-05	Heptapeptide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE2528935C2 (de)	1986-06-26	Verfahren zur Herstellung Arginylreste enthaltender Peptide und hierbei eingesetzte Zwischenprodukte
CH653345A5 (de)	1985-12-31	Analoga des vasopressins.
CH622287A5 (en)	1981-03-31	Method for the determination of thrombin or of enzymes which cleave the substrates in the same way as thrombin, and use of the method
CH633523A5 (de)	1982-12-15	Verfahren zur herstellung von peptiden und peptidderivaten.
US4483794A (en)	1984-11-20	Analogs of neurohypophysial hormones
CH653346A5 (de)	1985-12-31	Analoga der neurohypophysaeren hormone oxytocin und vasopressin mit inhibierungseigenschaften gegenueber der aktivitaet dieser natuerlichen hormone.
CH649090A5 (de)	1985-04-30	Analoga von oxytocin und ihr herstellungsverfahren.
DE2830489A1 (de)	1979-01-25	Psychopharmakologisch wirksame peptide
EP0095557B1 (de)	1985-12-27	Polypeptide mit antagonistischen Eigenschaften gegenüber der Substanz P, Verfahren zu ihrer Herstellung, deren Verwendung und Verfahren zum Reinigen von Polypeptiden
DE2342862C3 (de)	1981-01-15	An beiden Kettenenden Reste von a -Aminooxycarbonsäuren aufweisende Peptide mit ACTH-Wirkung, Verfahren zu ihrer Herstellung und diese Peptide enthaltende Arzneimittel
EP0151016A2 (en)	1985-08-07	Arginine vasopressin antagonists
CH422813A (de)	1966-10-31	Verfahren zur Herstellung neuer Polypeptide
EP0258784B1 (de)	1992-12-09	Chromogene Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung
DE2341775C3 (de)	1980-12-18	In N-terminaler Stellung den Rest einer Aminooxysäure aufweisende Peptide mit ACTH-Wirkung, Verfahren zu ihrer Herstellung sowie diese Peptide enthaltende Arzneimittel
CH640510A5 (de)	1984-01-13	Verfahren zur herstellung und reinigung von sekretin.
EP0003122B1 (de)	1981-04-29	Verfahren zur Herstellung cysteinhaltiger Peptide
DE3320189A1 (de)	1983-12-08	Analoga von neurohypophysaeren hormonen mit inhibierungswirkungen, ihre herstellung und pharmazeutische zusammensetzungen
EP0001075B1 (de)	1980-11-26	Teilgeschützte Human-Insulin-A-Kette und Verfahren zu ihrer Herstellung
DE2347456A1 (de)	1974-04-11	Polypeptide und verfahren zu deren herstellung
Zaoral et al.	1979	[1-β-Mercaptopropionic acid, 8-norarginine] vasopressin and [1-β-mercaptopropionic acid, 8-D-norarginine] vasopressin. Two analogs with strong biological effects
DE1965101A1 (de)	1971-07-01	Pentadekapeptide mit adrenocorticotroper Wirkung und Verfahren zu ihrer Herstellung